Evaluation of TGFβ, XPO4, elF5A2 and ANGPTL4 as biomarkers in HCC

Experimental and Therapeutic Medicine

Volumn 5, Issue 1, 2013, Pages 119-127

  Zhang, Hao ^a   Wei, Shi ^a   Ning, Song ^a   Jie, Yungliu ^a   Ru, Yukang ^a   Gu, Yuchun ^b  

^a FUDAN UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

ANGPTL4; Biomarker; eLF5A2; Hepatocellular carcinoma; TGF 1; XPO4

Indexed keywords

ANGPTL4 PROTEIN; INITIATION FACTOR 5A; INITIATION FACTOR 5A2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; UNCLASSIFIED DRUG; XPO4 PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CYTOKINE PRODUCTION; CYTOPLASM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

EID: 84869485418     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.750     Document Type: Article

References (26)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. Fabregat I: Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 15: 513-520, 2009.
3. Dong ZZ, Yao DF, Yao M, et al: Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 7: 288 -295, 2008.
4. Mishra L, Derynck R and Mishra B: Transforming growth factor-beta signaling in stem cells and cancer. Science 310: 68-71, 2005.
5. Kim SH, Ahn S and Park CK: Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy. Hepatobiliary Pancreat Dis Int 11: 51-59, 2012.
6. Coulouarn C, Factor VM and Thorgeirsson SS: Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47: 2059-2067, 2008.
7. Zender L, Xue W, Zuber J, et al: An oncogenomics-based in vivo RNAi screen identifes tumor suppressors in liver cancer. Cell 135: 852-864, 2008.
8. Kurisaki A, Kurisaki K, Kowanetz M, et al: The mechanism of nuclear export of Smad3 involves exportin 4 and Ran. Mol Cell Biol 26: 1318-1332, 2006.
9. Liang XT, Pan K, Chen MS, et al: Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol 26: 544-549, 2011.
10. Fransvea E, Mazzocca A, Antonaci S and Giannelli G: Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 49: 839-850, 2009.
11. Perdiguero EG, Galaup A, Durand M, et al: Alteration of developmental and pathological retinal angiogenesis in angptl4 - defcient mice. J Biol Chem 286: 36841-36851, 2011.
12. Li H, Ge C, Zhao F, et al: Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinoma. Hepatology 54: 910-919, 2011.
13. Huang RL, Teo Z, Chong HC, et al: ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters. Blood 118: 3990-4002, 2011.
14. Padua D, Zhang XH, Wang Q, et al: TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4 Cell 133: 66-77, 2008.
15. Yao FY, Ferrell L, Bass NM, et al: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33: 1394-1403, 2001.
16. Gao Q, Qiu SJ, Fan J, et al: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593, 2007
17. Battifora H: The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 55: 244-248, 1986.
18. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high - throughput molecular profling of tumor specimens. Nat Med 4: 844-847, 1998.
19. Xiang ZL, Zeng ZC, Tang ZY, et al: Potential prognostic biomarkers for bone metastasis from hepatocellular carcinoma. Oncologist 16: 1028-1039, 2011.
20. Giannelli G, Mazzocca A, Fransvea E, Lahn M and Antonaci S: Inhibiting TGFβ signaling in hepatocellular carcinoma. Biochim Biophys Acta 1815: 214-223, 2011.
21. Picon A, Gold LI, Wang J, Cohen A and Friedman E: A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1. Cancer Epidemiol Biomarkers Prev 7: 497-504, 1998.
22. Mishra L, Banker T, Murray J, et al: Liver stem cells and hepatocellular carcinoma. Hepatology 49: 318-329, 2009
23. Baek HJ, Lim SC, Kitisin K, et al: Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology 48: 1128-1137, 2008.
24. Cazes A, Galaup A, Chomel C, et al: Extra cellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. Circ Res 99: 1207-1215, 2006.
25. Hasita H, Komohara Y, Okabe H, et al: Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 101: 1913-1919, 2010.
26. Shibata K, Nakayama T, Hirakawa H, Hidaka S and Nagayasu T: Clinicopathological significance of angiopoietin-like protein 4 expression in oesophageal squamous cell carcinoma. J Clin Pathol 63: 1054-1058, 2010.